Latest news about Lupin
Lupin Receives US FDA Approval for Sodium Zirconium Cyclosilicate Oral Suspension
Lupin
2,201.80
+0.30(+0.01%)
Company Performance:
View Company Insights1D+0.01%
1M-11.16%
6M-0.79%
1Y+13.48%
5Y+137.62%
More news about Lupin
10Aug 26
Lupin's U.S. Business Anticipated To Return To Growth Starting Fiscal Year '28, Supported By Strong Pipeline
Lupin anticipates its U.S. business to return to growth starting fiscal year '28. The recovery is expected to be driven by a strong pipeline comprising exclusive first-to-file products, biosimilars, and 505(B)(2) formulations. These differentiated product categories are central to the company's U.S. market strategy, targeting high-value segments with competitive advantages such as market exclusivity and premium pricing potential.
10Aug 26
Lupin Latest Results: U.S. business forecast at $1.1B–$1.2B, 25% EBITDA margin guided
Lupin has confirmed expectations for high single-digit revenue growth and approximately 25% EBITDA margins for the current year. The U.S. business is forecasted between $1.1 billion and $1.2 billion, driven by base business growth, injectable launches, and Pegfilgrastim. Increased competition from Mirabegron and Tolvaptan is expected to partially offset these growth drivers.
08Aug 26
Lupin publishes Q1FY26 results in newspapers, confirming ₹27,146 mn profit
Lupin Limited complied with SEBI regulations by publishing its Q1FY26 unaudited financial results in newspapers on August 8, 2026. The publication reaffirms key metrics: standalone PAT rose 27% YoY to ₹27,146 million, while consolidated revenue surged 32% to ₹82,769 million. The results, approved by the Board on August 6, 2026, highlight strong performance in the Pharmaceuticals segment and successful integration of VISUfarma B.V., despite minor impairment charges.
05Aug 26
Lupin Ltd. Records ₹29.03 Crore Block Trade on NSE at ₹2388.30 Per Share
Lupin Ltd. executed a block trade on the NSE valued at ₹29.03 crores, involving approximately 1,21,534 shares at ₹2388.30 per share. Block trades of this magnitude are typically associated with institutional-level activity and are conducted outside the open market to limit price impact. The transaction highlights notable movement in Lupin's stock on the NSE.
05Aug 26
Lupin shareholders approve ₹18 dividend, Deloitte audit
Lupin Limited’s 44th AGM concluded with shareholders approving a ₹18 per share final dividend for FY26, reappointing Nilesh D. Gupta as director, and naming Deloitte Haskins & Sells as statutory auditors. All five ordinary resolutions passed with overwhelming majority support, reflecting strong stakeholder confidence in the company’s governance and financial direction.
31Jul 26
Lupin Receives U.S. FDA Approval for Diazepam Injection USP
Lupin has secured U.S. FDA approval for Diazepam Injection USP, reinforcing its presence in the U.S. generics market. The approval enables Lupin to participate in the injectable segment, reflecting the company's ongoing efforts to expand its pharmaceutical portfolio in the United States.
31Jul 26
Lupin launches Sugammadex Injection in US after FDA approval
Lupin Limited launched Sugammadex Injection in the United States on July 31, 2026, following FDA approval. The product serves as a bioequivalent generic to Merck's Bridion, targeting the reversal of neuromuscular blockade in surgical settings. Available in 200 mg and 500 mg strengths, this launch enhances Lupin's complex generics offering in the lucrative US market.
23Jul 26
Lupin to Host Q1 FY27 Earnings Call on August 7 at 16:30 IST
Lupin Limited has scheduled its Q1 FY27 earnings call for August 7, 2026, at 16:30 IST on Zoom, to discuss financial performance for the quarter ended June 30, 2026. The regulatory filing was signed by Company Secretary Amit Kumar Gupta, and participants must register in advance via the enclosed invitation link.
21Jul 26
Lupin spins out oncology programs to Kaveri Therapeutics
Lupin Limited announced the spin-out of oncology programs LNP7457 and LNP8701 to Kaveri Therapeutics, acquiring an 82.2% stake through its subsidiary Lupin Inc. The USD 1.6 million transaction includes exclusive licensing rights and seed funding to advance global clinical trials for solid tumors. Kaveri, led by CEO Kristi Jones and CMO Dr. Robert Pierce, will focus on biomarker-driven development for cancers including lung and pancreatic.
17Jul 26
Lupin Ltd. Records Rs. 27.12 Crore Block Trade on NSE at Rs. 2444.40 Per Share
A block trade worth Rs. 27.12 crores was executed on the NSE for Lupin Ltd., involving approximately 1,10,946 shares at a price of Rs. 2444.40 per share. The transaction highlights notable institutional activity in the stock. Block trades of this scale are typically associated with large portfolio adjustments by institutional investors.
15Jul 26
Lupin Records ₹99.88 Crore Block Trade on BSE at ₹2497 Per Share
A block trade worth ₹99.88 crore was recorded on the BSE for Lupin, involving approximately 400000 shares transacted at ₹2497 per share. Such large-scale block trades are generally associated with institutional participation. The transaction highlights significant activity in the Lupin counter on the BSE.
14Jul 26
Lupin FY26 report shows 51% renewable energy use
Lupin Limited's Business Responsibility and Sustainability Report for FY26 reveals a 41% reduction in Scope-1 and Scope-2 emissions and 51% renewable energy usage in India. The company maintained water-positive status, processed 3,717 tonnes of plastic waste, and achieved zero fatalities with 35,462 employee volunteering hours.
14Jul 26
Lupin fixes July 17 record date for ₹18 dividend
Lupin Limited has fixed July 17, 2026, as the record date for a ₹18 per share final dividend, subject to shareholder approval at the 44th AGM on August 4, 2026. The AGM will be held via video conferencing, with remote e-voting available from July 31 to August 3. Key business includes the adoption of financial statements, dividend declaration, and the appointment of statutory auditors.
06Jul 26
Lupin ranks 318th on TIME and Statista sustainability list
Lupin Limited secured the 318th position on TIME and Statista's World's Most Sustainable Companies 2026 list, selected from over 5,000 global organizations. The ranking evaluated firms on 20+ sustainability indicators, with Lupin being one of 16 Indian companies included. The company's recent ESG milestones include a CDP 'A' rating for Climate Change and Water Security, and an S&P Global CSA score of 91 in 2025.
02Jul 26
Lupin Somerset facility receives VAI status from US FDA
Lupin announced that its Somerset, New Jersey facility received an Establishment Inspection Report (EIR) from the U.S. FDA with a Voluntary Action Indicated (VAI) classification. The inspection took place from April 13, 2026, to April 17, 2026. Managing Director Nilesh Gupta highlighted the outcome as a reflection of the company's commitment to quality and compliance.
02Jul 26
Lupin Secures EMA Approval to Expand NaMuscla for Pediatric Use
Lupin has secured EMA approval to expand NaMuscla's marketing authorization to include pediatric indications, introducing 62 mg and 83 mg capsule strengths alongside the existing 167 mg. The approval covers children aged 6–11 years weighing at least 20 kg, adolescents, and adults with non-dystrophic myotonic disorders, reinforcing NaMuscla's position as the only approved treatment for myotonia symptoms in NDM in Europe.
02Jul 26
Lupin unit Nanomi completes MPPI stake acquisition
Lupin increased its indirect ownership in Multicare Pharmaceuticals Philippines to 99.89% through its subsidiary Nanomi B.V. effective July 01, 2026. The consolidation involved acquiring 11,794,497 shares and a buyback of 61,118 shares, with another buyback for 30,559 shares in progress.
27Jun 26
Lupin gets tentative US FDA nod for Enzalutamide Tablets
Lupin received tentative approval from the U.S. FDA for its Enzalutamide Tablets across four strengths: 40 mg, 80 mg, 120 mg, and 160 mg. The 40 mg and 80 mg strengths are bioequivalent to the reference listed drug Xtandi® Tablets, marketed by Astellas Pharma Inc. The additional 120 mg and 160 mg strengths offer alternative dosing options. Lupin distributes products in over 100 markets and operates 15 manufacturing sites and 7 research centers globally.
18Jun 26
Lupin Launches Azilsartan Medoxomil Tablets in US Market with 180-Day Exclusivity
Lupin Limited launched Azilsartan Medoxomil Tablets (40mg and 80mg) in the US on June 17, 2026, for the treatment of hypertension in adults. As the exclusive first-to-file, Lupin is eligible for 180-day generic drug exclusivity on the product, which had estimated annual sales of USD 53.5 million per IQVIA MAT April 2026 data. The launch reinforces Lupin's cardiovascular portfolio and its broader presence across multiple U.S. therapy segments.
09Jun 26
Lupin partners with ERN to launch Luforbec in Spain
Lupin Limited has partnered with LABORATORIOS ERN S.A. to launch Luforbec® (beclometasone/formoterol) 100/6 pMDI in Spain for adult asthma and COPD. The collaboration combines Lupin's respiratory expertise with ERN's local market reach to enhance patient access. The product is indicated for patients not adequately controlled on ICS or LABA therapies.
04Jun 26
Lupin receives US FDA approval for interchangeable Ranluspec injection
Lupin Limited secured U.S. FDA approval for Ranluspec, the only interchangeable biosimilar ranibizumab in the U.S. market available in vials and pre-filled syringes. The drug is approved in 0.3 mg and 0.5 mg strengths for treating various retinal diseases. Leadership emphasized the strategic importance of this approval for expanding the company's complex biologics portfolio.
03Jun 26
Lupin and Natco Secure FDA Approval for Eribulin Mesylate Injection with $43.7 Million Annual U.S. Sales Potential
Lupin Limited and Natco have obtained FDA approval for Eribulin Mesylate Injection, indicated for metastatic breast cancer and liposarcoma. The approval covers a product with an estimated annual U.S. sales potential of $43.7 million. This development reinforces both companies' commitment to expanding their oncology generics portfolio in the United States.
01Jun 26
Lupin CFO Swaminathan Says Company Targeting Large Specialty Deals While Maintaining Debt and Risk Discipline
Lupin's CFO Swaminathan has signaled the company's intent to pursue large specialty deals as a strategic priority. The management is simultaneously focused on maintaining discipline around debt levels and risk exposure. This approach reflects Lupin's commitment to balancing growth ambitions with financial prudence. The statement underscores the pharmaceutical company's measured strategy in navigating specialty market opportunities.
30May 26
Lupin subsidiary delays Multicare stake buy to July 2026
Lupin Limited announced that its wholly owned subsidiary, Nanomi B.V., has delayed the acquisition of a minority stake in Multicare Pharmaceuticals Philippines, Inc. from the end of May 2026 to July 2026. The transaction, signed on April 01, 2026, remains subject to specific closing conditions.
29May 26
Lupin shares Phase 1 data on LNP8701 at ASCO 2026
Lupin Limited shared Phase 1a trial results for LNP8701 at the ASCO 2026 Annual Meeting, indicating the SOS1 inhibitor was well tolerated with favorable anti-tumor activity. The study reported stable disease in patients undergoing monotherapy, with plans to continue efficacy studies in a phase 1b trial in India.
26May 26
Lupin to attend BofA, Morgan Stanley, Citi investor meets
Lupin Limited announced its participation in analyst and institutional investor meets scheduled for June 02, 03, and 04, 2026. The events include the BofA Securities 2026 India Conference, Morgan Stanley India Investment Forum 2026, and Citi India Conference 2026. The disclosure, made under Regulation 30 of the SEBI Listing Regulations, was confirmed by Company Secretary Amit Kumar Gupta.
23May 26
Lupin enters China market with Oseltamivir approval
Lupin has received approval from China's National Medical Products Administration for its Oseltamivir Phosphate Oral Suspension, marking its first product entry into the Chinese market. The approval was granted for an Abbreviated New Drug Application in partnership with Yabao Pharmaceuticals. This milestone represents a significant step in Lupin's global expansion strategy.
21May 26
Lupin Records Rs. 17.19 Crore Block Trade on NSE at Rs. 2289.30 Per Share
Lupin recorded a block trade on the NSE involving approximately 75,090 shares executed at Rs. 2289.30 per share, with a total transaction value of Rs. 17.19 crores. Such large-volume trades are typically carried out by institutional investors or high-net-worth participants outside the regular order book to minimize price impact.
20May 26
Lupin Debuts in Dow Jones Best-in-Class Indices 2026
Lupin Limited debuted in the Dow Jones Best-in-Class (DJBIC) Indices 2026, featuring in both the World and Emerging Markets indices based on its strong ESG performance. This inclusion follows the company's ranking among the top 1% globally in the S&P Global Corporate Sustainability Assessment (CSA) 2025, where it achieved an industry-leading score of 91/100. The indices track the top 10% of the largest companies in the S&P Global Broad Market Index by sustainability performance.
19May 26
Lupin Inaugurates Atharv Ability Neuro-Rehabilitation Center in Delhi, Expanding Specialized Care in North India
Lupin Limited launched its third Atharv Ability neuro-rehabilitation center in Naraina Vihar, Delhi on May 15, 2026, under Regulation 30 disclosure. The facility offers advanced care including end-effector robotics, AI-based balance systems, and multidisciplinary therapies for neurological conditions such as stroke, Parkinson's disease, and cerebral palsy, expanding specialized care access across North India.
19May 26
Lupin Receives Tentative US FDA Approval for Refevenacin Inhalation Solution
Lupin has obtained a tentative approval from the US FDA for Refevenacin Inhalation Solution. The tentative approval indicates the product has met all regulatory requirements set by the US FDA. This development highlights Lupin's continued efforts to expand its respiratory product portfolio in the United States.
14May 26
Lupin Receives U.S. FDA Approval for Famotidine Injection
Lupin has obtained U.S. FDA approval for Famotidine Injection, adding to its injectable generics portfolio in the United States. Famotidine is a histamine-2 blocker used for treating conditions associated with excess stomach acid. This regulatory milestone highlights Lupin's continued focus on expanding its presence in the U.S. pharmaceutical market through new product approvals.
11May 26
Lupin Q4 FY26 Beats Estimates; CLSA, Nomura & Morgan Stanley Bullish on Strong US-Led Performance
Lupin's Q4 FY26 results beat estimates with consolidated net profit rising to ₹14.6 billion and EBITDA margin expanding to 33.6%. CLSA maintained Outperform at ₹2,690, Nomura maintained Buy at ₹2,580, and Morgan Stanley maintained Equal-weight at ₹2,386, all citing strong US-led performance. Management guided for high-single to low-double-digit FY27 revenue growth and 25% EBITDA margin, while flagging potential US margin headwinds amid competition in key products.
11May 26
Lupin Targets $1B+ US Revenue and 25% EBITDA Margins for FY27 Amid Pipeline Expansion
Lupin has outlined its FY27 financial roadmap, projecting US revenue above $1 billion despite anticipated high single-digit to low double-digit declines from competition on Tolvaptan and Mirabegron. The company targets strong single-digit revenue growth, ~25% EBITDA margins, a 25-26% effective tax rate, and over 20 product launches, while planning key FY28 launches including Ranibizumab and Dulera. Its longer-term strategy focuses on complex generics and biosimilars through 2028–2031.
08May 26
Lupin Limited Recommends Deloitte Haskins & Sells as Statutory Auditors for a Five-Year Term
Lupin Limited's Board of Directors, at its meeting on May 07, 2026, recommended the appointment of Deloitte Haskins & Sells Chartered Accountants LLP (Firm Registration No. 117364W/W100739) as Statutory Auditors for a first term of five consecutive years, from the conclusion of the Forty-Fourth AGM to the Forty-Ninth AGM. The recommendation follows the completion of the second consecutive five-year term of the existing auditors, B S R & Co. LLP Chartered Accountants. The appointment remains subject to approval by the company's members at the ensuing AGM. The intimation was made in compliance with Regulation 30 of the SEBI Listing Regulations.
05May 26
Lupin Limited Announces Special Window for Transfer and Dematerialization of Physical Shares
Lupin Limited has opened a special window from February 05, 2026 to February 04, 2027 for the transfer and dematerialization of physical securities sold or purchased prior to April 01, 2019, in compliance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. Transfer requests previously rejected or returned due to document deficiencies must be re-lodged with the RTA, MUFG Intime India Pvt. Ltd., within the stipulated window period. Upon successful transfer, shares will be credited in demat mode only and will be subject to a one-year lock-in period from the date of registration. Cases involving disputes between transferor and transferee, or securities already transferred to the IEPF, are excluded from this special window.
05May 26
Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid, Generic of Ravicti®
Lupin Limited received U.S. FDA approval on May 5, 2026, for its ANDA for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL, a generic equivalent of Ravicti® Oral Liquid by Horizon Therapeutics U.S. Holding LLC. The product is indicated for the chronic management of patients with urea cycle disorders that cannot be controlled by dietary protein restriction and/or amino acid supplementation alone. The RLD Ravicti® recorded product sales of USD 337 million for the year ended December 2025, as per IQVIA MAT DEC 2025 data.
04May 26
Lupin Allots 36,752 Equity Shares Under ESOP, Paid-Up Capital Rises to ₹91,44,31,726
Lupin Limited, on May 4, 2026, allotted 36,752 fully paid-up equity shares of ₹2/- each under its Employee Stock Option plans, following the exercise of vested options by employees and subsidiary staff. The allotment was approved by the company's Operations and Finance Committee at its meeting on the same date. As a result, the company's issued and paid-up share capital has increased to ₹91,44,31,726, comprising 45,72,15,863 equity shares of ₹2/- each. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
25Apr 26
Lupin Limited Announces Q4 FY26 Earnings Call Scheduled for May 8, 2026
Lupin Limited has officially announced its Q4 FY26 earnings call scheduled for May 8, 2026 at 16:00 hrs IST via Zoom platform. The announcement was made in compliance with SEBI Listing Regulations, with proper notifications sent to NSE and BSE exchanges, and includes comprehensive stakeholder access arrangements.
23Apr 26
Lupin Limited Announces Board Meeting on May 7, 2026 for Q4FY26 Financial Results
Lupin Limited has scheduled its Board of Directors meeting for May 7, 2026, to approve audited financial results for Q4FY26 and consider dividend recommendations. The company has implemented a trading window closure from April 1, 2026, until May 10, 2026, affecting promoters, directors, and other designated personnel in compliance with SEBI regulations.
22Apr 26
Lupin Launches FDA-Approved Diabetes Drug in US Market with Multiple Dosage Strengths
Lupin Limited has officially launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States following FDA approval of its ANDA application. The diabetes treatment medication is available in four dosage strengths and is bioequivalent to AstraZeneca's Xigduo XR, representing a significant expansion of Lupin's pharmaceutical portfolio in the American market.
20Apr 26
Lupin Receives USFDA Form 483 With Three Observations For Somerset Facility
Lupin has received a Form 483 from the USFDA containing three observations for its Somerset, New Jersey manufacturing facility following an inspection conducted from April 13-17, 2026. The pharmaceutical company disclosed this regulatory development to stock exchanges and committed to addressing the compliance observations within the required timeframe while maintaining cGMP standards.
17Apr 26
Lupin Records Rs. 15.34 Crore Block Trade on NSE at Rs. 2310.70 Per Share
Lupin Ltd. executed a major block trade on NSE worth Rs. 15.34 crores involving approximately 66,399 shares at Rs. 2310.70 per share. The transaction represents significant institutional activity and demonstrates substantial market interest in the pharmaceutical company's stock.
17Apr 26
Lupin's US Subsidiary Settles Antitrust Dispute with Humana for $30 Million
Lupin Limited disclosed that its wholly-owned US subsidiary Lupin Pharmaceuticals Inc. has reached a $30 million settlement with Humana Inc. in antitrust litigation related to alleged anticompetitive behavior in generic pharmaceuticals. The subsidiary denies all allegations but chose to settle to avoid litigation costs and uncertainties, with the settlement amount already accounted for in previous financial results.
11Apr 26
Lupin Launches Dapagliflozin Tablets in US Following FDA Approval
Lupin Limited has successfully launched Dapagliflozin Tablets in 5mg and 10mg strengths in the United States following FDA approval of its Abbreviated New Drug Application. The tablets are bioequivalent to Farxiga® and represent another milestone in Lupin's diabetes care portfolio expansion in the American pharmaceutical market.
09Apr 26
Lupin Limited Grants 6,495 Stock Options to Employees Under ESOP Plan
Lupin Limited granted 6,495 stock options to employees under its 2011 ESOP plan, approved by the Nomination and Remuneration Committee on April 09, 2026. The options carry an exercise price of ₹2.00 each, with a structured vesting schedule of 25% annually over four years starting one year from the grant date. Each option entitles holders to subscribe to one equity share upon vesting.
08Apr 26
Biocon Gets FDA Nod for Dapagliflozin Tablets in 5mg and 10mg Strengths
Biocon Pharma Limited has secured US FDA approval for Dapagliflozin Tablets in 5mg and 10mg strengths, indicated for type 2 diabetes treatment and reducing heart failure hospitalization risk. This regulatory milestone enhances Biocon's comprehensive diabetes portfolio and will be manufactured at FDA-approved facilities.
07Apr 26
Lupin Limited Receives Great Place To Work® Certification™ for 2026-27
Lupin Limited has received the Great Place To Work® certification for 2026-27, becoming one of select pharmaceutical companies to achieve this global workplace excellence recognition. The certification was earned through a comprehensive evaluation with 85% employee participation across all subsidiaries and geographies. In FY25, Lupin invested INR 40 billion in employee benefits and provided 1,253,456 hours of employee training for its workforce of over 24,000 professionals globally.
07Apr 26
Lupin Limited Submits Quarterly Compliance Certificate for Q4 FY26
Lupin Limited has submitted its quarterly compliance certificate for Q4 FY26 pursuant to SEBI Regulation 74(5), confirming proper handling of dematerialized securities. The certificate was issued by registrar MUFG Intime India Private Limited and submitted to stock exchanges on April 6, 2026. This represents standard regulatory compliance ensuring transparency in share transfer processes for the quarter ended March 31, 2026.
02Apr 26
Lupin Completes VISUfarma Acquisition, Expands Eye Care Portfolio to 60+ Products
Lupin Limited successfully completed its strategic acquisition of VISUfarma B.V., a European specialty pharmaceutical company, through its Netherlands subsidiary Nanomi B.V. The transaction adds over 60 branded eye care products spanning dry eye, glaucoma, and retinal health segments, while bringing €53 million in revenue and strengthening Lupin's commercial footprint across key European markets including Italy, UK, Spain, Germany, and France.
02Apr 26
Lupin Unit Plans 43.38% Acquisition in Philippines for USD 39.6 Million
Lupin Limited announced its subsidiary Nanomi B.V. will acquire 43.38% stake in Multicare Pharmaceuticals Philippines for up to USD 39.6 million, aiming for complete ownership by May 2026. The acquisition will increase Nanomi's shareholding from 56.28% to 99.66% in the Philippines-based pharmaceutical trading and distribution company.
01Apr 26
Lupin Ltd Records Major Block Trade Worth Rs. 236.53 Crores on NSE
Lupin Ltd recorded a major block trade on NSE involving 1,031,642 shares worth Rs. 236.53 crores at Rs. 2292.80 per share. The transaction highlights significant institutional activity and demonstrates strong liquidity in the pharmaceutical company's equity.
01Apr 26
Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
Lupin Limited has received tentative approval from the U.S. FDA for its Sugammadex Injection in 200 mg/2 mL and 500 mg/5 mL dosage strengths. The product is bioequivalent to Merck's Bridion Injection and is indicated for reversing neuromuscular blockade in adults and pediatric patients aged 2 years and older during surgical procedures.
30Mar 26
Lupin's Philippines Unit Executes Share Buyback, Increases Nanomi's Stake to 56.28%
Lupin's Philippines subsidiary Multicare Pharmaceuticals executed a strategic share buyback of 2.8 million shares, automatically increasing Nanomi's ownership from 51% to 56.28%. The transaction utilized MPPI's retained earnings and was properly disclosed under SEBI regulations, with the company reporting PHP 2,096.60 million in turnover and PHP 1,265.50 million net worth.
25Mar 26
Lupin Gets Tentative U.S. FDA Approval For Pitolisant Tablets 4.45mg And 17.8mg
Lupin Limited has secured tentative approval from the U.S. FDA for its Pitolisant Tablets in two strengths (4.45mg and 17.8mg), which are bioequivalent to the reference drug Wakix®. The tablets will be manufactured at the company's Nagpur facility, strengthening Lupin's presence in the central nervous system therapy segment and expanding its generic pharmaceutical portfolio.
24Mar 26
Lupin Allots 135,892 Equity Shares Under Employee Stock Option Plan
Lupin Limited allotted 135,892 equity shares under its ESOP on March 24, 2026, to employees of the company and its subsidiaries. The shares, with a face value of ₹2/- each, were issued following the exercise of vested stock options. This allotment increased Lupin's paid-up share capital to ₹91,43,58,222, comprising 45,71,79,111 equity shares. The decision was approved by the Operations and Finance Committee and disclosed to stock exchanges in compliance with SEBI regulations.
19Mar 26
Lupin Announces Strategic Expansion of Dabhasa Manufacturing Facility in India
Lupin Manufacturing Solutions has announced a strategic expansion of its Dabhasa manufacturing facility in India, introducing two specialized peptide manufacturing units and enhanced infrastructure to boost development and manufacturing capabilities. The expansion aims to support growing global demand for complex pharmaceutical solutions, particularly peptides and biologic ADCs, reinforcing LMS's position in the global peptide ecosystem.
18Mar 26
Lupin Records ₹32.74 Crore Block Trade on NSE at ₹2,300.20 Per Share
Lupin Ltd. executed a significant block trade on NSE worth ₹32.74 crores, involving approximately 142,339 shares at ₹2,300.20 per share. The transaction highlights substantial institutional trading activity in the pharmaceutical company's stock and represents a notable block deal in the current market environment.
09Mar 26
Lupin Reports Cargo Movement Disruptions Due to Container Delays at European and Middle Eastern Ports
Lupin reports cargo movement disruptions due to container delays at European and Middle Eastern ports, affecting its supply chain operations. The pharmaceutical company also faces potential cost pressures from higher oil prices that may increase solvent costs. These challenges highlight the operational difficulties pharmaceutical manufacturers are experiencing due to global supply chain issues and commodity price volatility.
09Mar 26
Lupin's Ankleshwar Manufacturing Facility Receives FDA Form-483 with Two Observations
Lupin Limited disclosed that its Ankleshwar manufacturing facility in India received a Form-483 from the U.S. FDA containing two observations after a five-day inspection concluded on March 07, 2026. The company has committed to addressing the FDA's findings within the required timeframe while maintaining its focus on Current Good Manufacturing Practice standards across all facilities.
04Mar 26
Lupin GST Inspection Concludes With No Adverse Findings, Zero Financial Impact
Lupin Limited has successfully concluded a GST Department inspection at its Mumbai registered office with no adverse findings reported. The inspection by the Assistant Commissioner of State Tax, Maharashtra, was conducted under Section 67 of Maharashtra GST Act, 2017, focusing on GST payment documentation and input tax credit claims, with the company confirming zero financial impact from the proceedings.
27Feb 26
Lupin: Nanomi B.V. Delays Purchase of Visufarma B.V.; Deal Now Anticipated to Finalize in April 2026, Awaiting Required Approvals
Lupin Limited has announced a timeline extension for its subsidiary Nanomi B.V.'s acquisition of Netherlands-based VISUfarma B.V., pushing the completion date from February 28, 2026 to April 2026. The delay is attributed to pending satisfaction of specific closing conditions required for the cross-border transaction, with the deal still subject to regulatory approvals and other conditions precedent.
27Feb 26
Lupin Receives Satisfactory US FDA Inspection Report for Goa Manufacturing Facility
Lupin Limited announced receipt of a satisfactory Establishment Inspection Report from the US FDA for its Goa manufacturing facility, with Voluntary Action Indicated classification. The inspection was conducted from November 10-21, 2025, and the positive outcome ensures continued manufacturing operations and US market access while demonstrating the company's commitment to quality excellence and regulatory compliance.
26Feb 26
Lupin Announces CEO Vinita Gupta's Recognition on 2026 CNBC Changemakers List
Lupin Limited announced through a Regulation 30 disclosure that CEO Vinita Gupta has been recognized on the prestigious 2026 CNBC Changemakers list of Women Transforming Business. Under her leadership, Lupin has grown to become the third-largest generic medicine supplier to the U.S. and the world's seventh-largest pharmaceutical company by volume, with recent achievements including FDA approval for its first biosimilar and plans for a new inhalation facility in Florida.
26Feb 26
Lupin Achieves Global Leadership in ESG with Top Rankings in S&P Corporate Sustainability Assessment 2025
Lupin Limited has achieved the No. 1 position globally in pharmaceuticals and leads all sectors in India in the S&P Global Corporate Sustainability Assessment 2025, scoring 91 out of 100 and ranking in the top 1% worldwide. This marks the company's third consecutive inclusion in the Sustainability Yearbook 2026, with only 848 companies out of more than 9,200 assessed earning this recognition. The achievement reflects Lupin's sustained commitment to ESG principles, responsible business practices, and positive stakeholder impact across its global operations.
25Feb 26
Lupin Gets FDA Approval For Brivaracetam Oral Solution, Estimated U.S. Sales Of $135 Million
Lupin Limited has secured FDA approval for its Brivaracetam Oral Solution 10 mg/mL and commenced commercial launch in the U.S. market. The generic formulation serves as a bioequivalent to UCB's Briviact, targeting the treatment of partial-onset seizures across all age groups from 1 month onwards, with the reference drug generating estimated annual sales of USD 135 million in the American market.
23Feb 26
Lupin Receives European Commission Approval for Biosimilar Ranibizumab
Lupin Limited announced European Commission approval for its biosimilar ranibizumab, branded as Ranluspec™, available in vials and pre-filled syringes formats. The biosimilar treats various eye conditions including age-related macular degeneration and diabetic complications. Sandoz will handle commercialization across the European Union excluding Germany, while France will see dual commercialization through both Sandoz and Biogaran.
14Feb 26
Lupin Limited Announces Anand Kripalu as Independent Director with Strong Mandate
Lupin Limited has officially appointed Anand Kripalu as Independent Director following overwhelming shareholder approval through postal ballot process. The appointment received 96.53% votes in favor with strong 90.17% participation rate across all shareholder categories. Kripalu brings extensive leadership experience from FMCG sector including roles at EPL Limited, Diageo India, Mondelez International, and Unilever, strengthening Lupin's board composition for strategic growth initiatives.
13Feb 26
Lupin Allots 75,273 Equity Shares Under Employee Stock Option Plan
Lupin Limited allotted 75,273 equity shares under its ESOP on February 13, 2026, following approval by the Operations and Finance Committee. The shares, with a face value of ₹2 each, were granted to employees upon exercising vested options. Post-allotment, the company's paid-up capital stands at ₹91,40,86,438 comprising 45,70,43,219 equity shares, demonstrating the company's commitment to employee equity participation.
13Feb 26
Lupin Board Approves Q3 FY26 Results with Strong 26.4% Sales Growth
Lupin Limited's Board of Directors approved strong Q3 FY26 financial results with consolidated sales growing 26.4% to ₹71,005 million. The company demonstrated robust operational efficiency with EBITDA margins expanding to 33.5% and net profit increasing 37.4% to ₹11,805 million, driven primarily by exceptional 54% growth in the US market.
10Feb 26
Lupin Settles Patent Dispute with Astellas Pharma for USD 90 Million
Lupin Limited has resolved its patent infringement dispute with Astellas Pharma entities through a USD 90 million settlement agreement regarding its Mirabegron product. The settlement includes a USD 75 million prepaid option payment and additional per-unit license fees for sales through September 2027. This agreement allows Lupin to continue selling its Mirabegron product while resolving all pending litigation, providing operational certainty and eliminating legal risks for the pharmaceutical company.
04Feb 26
Lupin Launches Topiramate Extended-Release Capsules in U.S. Market with USD 164 Million Sales Potential
Lupin has launched Topiramate Extended-Release Capsules in the U.S. market, targeting an estimated annual sales opportunity of USD 164 million. This product launch strengthens the company's generic pharmaceutical portfolio in the United States and demonstrates its continued expansion strategy in key international markets.
02Feb 26
Lupin Launches Dasatinib Tablets in US Market Following FDA Approval
Lupin has successfully launched Dasatinib tablets in the US market following FDA approval for its ANDA, developed in partnership with Pharmascience Inc. The bioequivalent tablets are available in six dosage strengths and indicated for various Philadelphia chromosome-positive cancer treatments in both adult and pediatric patients, with expected annual sales of USD 930 million.
02Feb 26
Lupin Announces Strategic TB Alliance Partnership for Telacebec Development
Lupin Limited has formally announced a strategic partnership with TB Alliance under SEBI Regulation 30 to advance Telacebec development for multiple mycobacterial diseases. The collaboration combines TB Alliance's drug development expertise with Lupin's global manufacturing, regulatory affairs, and supply chain capabilities to ensure equitable access to this investigational treatment for tuberculosis, leprosy, and Buruli ulcer.
01Feb 26
DGTR Finds Dumping of Ethambutol Hydrochloride Imports from China and Thailand, Flags Injury to Domestic Players
India's DGTR has issued preliminary findings concluding that Ethambutol Hydrochloride imports from China and Thailand constitute dumping practices. The trade regulator has identified this as causing material injury to domestic pharmaceutical manufacturers. This development could lead to protective measures benefiting Indian companies like Lupin that produce this anti-tuberculosis drug domestically.
29Jan 26
Lupin Ltd. Records Rs. 19.17 Crore Block Trade on NSE
Lupin Ltd. recorded a significant block trade on NSE worth Rs. 19.17 crores involving approximately 90,749 shares at Rs. 2,112.70 per share. The transaction reflects substantial institutional trading activity and demonstrates market participation through organized block trading mechanisms. Such large-scale transactions typically indicate strategic portfolio movements by institutional investors in the pharmaceutical company's shares.
28Jan 26
Lupin Limited Schedules Board Meeting on February 12, 2026 for Q3FY26 Financial Results Review
Lupin Limited has announced a Board of Directors meeting on February 12, 2026, to review and approve Q3FY26 unaudited financial results for the quarter and nine months ended December 31, 2025. The company has implemented a trading window closure from January 1, 2026, until February 15, 2026, affecting promoters, directors, and other designated persons in compliance with SEBI insider trading regulations.
27Jan 26
Lupin Limited Allots 169,140 Equity Shares Under Employee Stock Option Plan
Lupin Limited allotted 169,140 equity shares of ₹ 2 each under its ESOP on January 27, 2026, to employees of the company and subsidiaries. The allotment increased the company's paid-up share capital to ₹ 91,39,35,892, comprising 45,69,67,946 equity shares. The decision was approved by the Operations and Finance Committee and disclosed to stock exchanges in compliance with SEBI regulations.
23Jan 26
Lupin Limited Achieves Highest CDP ESG Rating for Climate Change and Water Security
Lupin Limited has received the highest 'A' leadership rating from Climate Disclosure Project (CDP) for both Climate Change and Water Security, marking significant improvement from previous years' ratings. The company also achieved an S&P Global ESG score of 91.00 in 2025, positioning it among elite global companies. This recognition reflects Lupin's commitment to sustainability through initiatives focused on climate risk mitigation, carbon emission reduction, and responsible water management across its global operations.
21Jan 26
Lupin Limited Partners with Galenicum for Semaglutide Distribution Across 23 Countries
Lupin Limited has announced a licensing and supply agreement with Galenicum Health for injectable Semaglutide across 23 countries including Canada, Europe, Southeast Asia and Latin America. Under the partnership, Galenicum will handle development and manufacturing while Lupin manages regulatory affairs and commercialization. The collaboration strengthens Lupin's diabetes care portfolio and positions the company to capitalize on growth opportunities in the expanding GLP-1 market for diabetes and obesity treatment.
19Jan 26
Lupin Limited Receives ESG Rating of 67 in Strong Category from Independent Assessment
Lupin Limited has been independently assigned an ESG rating of 67 by ESG Risk Assessments & Insights Limited, placing it in the Strong category. The assessment was conducted without company engagement, using only publicly available data, and was disclosed to stock exchanges on January 19, 2026, in compliance with SEBI regulations.
14Jan 26
Lupin Issues Postal Ballot Notice for Anand Kripalu's Independent Director Appointment
Lupin Limited has issued a postal ballot notice dated January 14, 2026, seeking shareholder approval for Mr. Anand Kripalu's appointment as Independent Director for a five-year term from February 01, 2026 to January 31, 2031. The remote e-voting process will be conducted through NSDL from January 15 to February 13, 2026, with results to be declared by February 17, 2026.
30Dec 25
Lupin VISUfarma Acquisition Delayed; GLP-1 Drug Deal Reinforces Growth Strategy
Lupin announces revised timeline for VISUfarma BV acquisition completion to February 28, 2026, extending from original end-2025 target. The company simultaneously reaffirms its strategic GLP-1 drug licensing deal with Gan & Lee Pharmaceuticals for Bofanglutide commercialization in India's substantial diabetes and obesity treatment market.
30Dec 25
Lupin Delays €190 Million VISUfarma Acquisition Timeline to February 2026
Lupin Limited has updated the timeline for its €190 million acquisition of Netherlands-based VISUfarma B.V., pushing the completion date from end-2025 to February 28, 2026. The transaction, being executed through wholly-owned subsidiary Nanomi B.V., will strengthen Lupin's European ophthalmology presence with VISUfarma's 60+ branded products and established market presence across major European countries.
30Dec 25
Lupin Secures Exclusive Rights for Innovative GLP-1 Drug in India Through Chinese Partnership
Lupin Ltd. has entered into an exclusive licensing agreement with China's Gan & Lee Pharmaceuticals for Bofanglutide, a fortnightly injectable GLP-1 drug for diabetes and obesity management in India. The drug offers potential advantages over existing treatments with its reduced dosing frequency. This strategic partnership aims to strengthen Lupin's position in the diabetes and obesity treatment markets in India.
19Dec 25
Lupin Signs Exclusive Licensing Agreement With Neopharmed For Gastroenterology Brand
Lupin has entered into an exclusive licensing agreement with Neopharmed for the gastroenterology brand Plasil, covering the Philippines and Brazil markets. This strategic partnership leverages Neopharmed's regional expertise and distribution networks to expand Lupin's international presence in the gastroenterology therapeutic segment.
18Dec 25
Lupin Signs Licensing Deal with Neopharmed for Plasil in Philippines and Brazil
Lupin's subsidiaries in the Philippines and Brazil have entered an exclusive licensing agreement with Neopharmed Gentili for the gastroenterology brand Plasil (metoclopramide). The deal grants Lupin exclusive marketing and promotional rights for Plasil in these markets. In the Philippines, Neopharmed will oversee product supply, while in Brazil, production will be transferred to Lupin's Medquimica facility. This partnership aims to strengthen Lupin's position in the gastroenterology segment across key emerging markets.
17Dec 25
Lupin Receives Positive CHMP Opinion for Biosimilar Ranibizumab Ranluspec
Lupin Limited has received a positive CHMP opinion from the European Medicines Agency for its biosimilar ranibizumab product Ranluspec, available in both vial and pre-filled syringe formulations. The recommendation is based on comprehensive clinical evidence including a 600-patient global Phase III trial conducted across multiple countries, with Sandoz Group AG set to commercialize the product across most EU markets.
17Dec 25
Lupin Receives US FDA EIR Approval for Nagpur Injectable Manufacturing Plant
Lupin has secured Establishment Inspection Report (EIR) approval from the US FDA for its injectable manufacturing facility in Nagpur. This regulatory milestone validates the facility's compliance with current Good Manufacturing Practices and strengthens Lupin's position in the US pharmaceutical market.
12Dec 25
Lupin Manufacturing Solutions Forms Strategic Alliance with PolyPeptide Group
Lupin Manufacturing Solutions, a subsidiary of Lupin Limited, has formed a long-term strategic alliance with PolyPeptide Group AG to strengthen global peptide supply chain capabilities and meet rising demand for peptide-based therapeutics. The partnership focuses on expanding sourcing options, integrating procurement planning, and ensuring quality delivery for both innovator and generic markets, with particular emphasis on metabolic disease therapies including GLP-1 treatments.
10Dec 25
Lupin Expands U.S. Presence with New Jersey Office and Updates ESOP Allotment
Lupin has expanded its U.S. presence with new corporate offices in Bridgewater, New Jersey, accommodating over 300 employees across various functions. The company's Operations and Finance Committee allotted 36,626 equity shares under ESOP, updating the share capital to ₹91,35,97,612 with total equity shares reaching 45,67,98,806, reflecting continued commitment to employee ownership and strategic growth.
01Dec 25
Lupin Secures U.S. FDA Approval for First Biosimilar Drug Armlupeg, Marking Entry into Biologics Market
Lupin Limited has received U.S. FDA approval for Armlupeg (pegfilgrastim-unne), its first biosimilar drug. Armlupeg is a biosimilar to Neulasta, with estimated annual sales of $1,295 million in the U.S. The 6mg/0.6mL injection is manufactured at Lupin's Biotech facility in Pune, India. It's indicated for reducing infection risk in cancer patients receiving chemotherapy and increasing survival in patients exposed to myelosuppressive radiation doses. This approval marks Lupin's entry into the biologics market, showcasing its advanced manufacturing capabilities and commitment to providing affordable medicines.
15Nov 25
Lupin's Nagpur Unit-1 Facility Aces U.S. FDA Inspection with Zero Observations
Lupin Limited's Nagpur Unit-1 oral solid dosage manufacturing facility successfully completed a product-specific Pre-Approval Inspection by the U.S. FDA with zero 483 observations. The inspection, conducted from November 10 to 14, focused on FDA regulation compliance. Nilesh Gupta, Managing Director of Lupin, emphasized the company's commitment to maintaining high quality, compliance, and safety standards across its facilities.
14Nov 25
Lupin Launches Risperidone Long-Acting Injectable in U.S., Marking Milestone for PrecisionSphere Platform
Lupin Limited has launched Risperidone Long-Acting Injectable in the U.S. market with 180-day Competitive Generic Therapy exclusivity. The antipsychotic medication is available in 25 mg, 37.5 mg, and 50 mg dosages. This marks the first commercial product using Lupin's proprietary PrecisionSphere™ long-acting injectable platform. The launch taps into a market with estimated sales of USD 187.00 million for the combined dosages. Lupin aims to expand its portfolio of complex products and explore partnerships to extend the use of its PrecisionSphere™ technology.
13Nov 25
Lupin Achieves Remarkable 91 S&P Global ESG Score, Setting New Industry Benchmark
Lupin Limited has attained an S&P Global ESG Score of 91, significantly above the pharmaceutical industry average of 28. This marks a substantial improvement from 17 in 2021 and a 15-point increase from the previous year. The company has made notable progress across environmental, social, and governance pillars, including increased use of renewable energy, promotion of diversity initiatives, and enhanced transparency in business practices. Ramesh Swaminathan, Executive Director at Lupin, emphasized the rarity of achieving a score above 90 globally and its implications for setting new industry standards.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life ScienceLupin
Mankind Pharma
Dr Reddys Laboratories
Laurus Labs
Aurobindo Pharma
1,902.40
(-0.08%)
8,597.00
(+0.32%)
4,896.50
(-2.17%)
1,432.20
(-0.40%)
1,120.00
(+1.11%)
2,201.80
(+0.01%)
2,384.00
(-0.04%)
1,174.70
(-0.45%)
1,802.00
(-1.26%)
1,621.30
(+0.83%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
